Diptasri Mandal
Professor (Tenured)
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (2)
Background: Clinical, molecular, and genetic epidemiology studies displayed remarkable differences between ever- and never-smoking lung cancer. Methods: We conducted a stratified multi-population (European, East Asian, and African descent) association study on 44,823 ever-smokers and 20,074 never-smokers to identify novel variants that were missed in the non-stratified analysis. Functional analysis including expression quantitative trait loci (eQTL) colocalization and DNA damage assays, and annotation studies were conducted to evaluate the functional roles of the variants. We further evaluated the impact of smoking quantity on lung cancer risk for the variants associated with ever-smoking lung cancer. Results: Five novel independent loci, GABRA4 , intergenic region 12q24.33 , LRRC4C , LINC01088, and LCNL1 were identified with the association at two or three populations ( P −8 ). Further functional analysis provided multiple lines of evidence suggesting the variants affect lung cancer risk through excessive DNA damage ( GABRA4 ) or cis -regulation of gene expression ( LCNL1 ). The risk of variants from 12 independent regions, including the well-known CHRNA5 , associated with ever-smoking lung cancer was evaluated for never-smokers, light-smokers (packyear ≤ 20), and moderate-to-heavy-smokers (packyear > 20). Different risk patterns were observed for the variants among the different groups by smoking behavior. Conclusions: We identified novel variants associated with lung cancer in only ever- or never-smoking groups that were missed by prior main-effect association studies. Impact: Our study highlights the genetic heterogeneity between ever- and never-smoking lung cancer and provides etiologic insights into the complicated genetic architecture of this deadly cancer.
Year:
2024
Background: Clinical, molecular, and genetic epidemiology studies displayed remarkable differences between ever- and never-smoking lung cancer. Methods: We conducted a stratified multi-population (European, East Asian, and African descent) association study on 44,823 ever-smokers and 20,074 never-smokers to identify novel variants that were missed in the non-stratified analysis. Functional analysis including expression quantitative trait loci (eQTL) colocalization and DNA damage assays, and annotation studies were conducted to evaluate the functional roles of the variants. We further evaluated the impact of smoking quantity on lung cancer risk for the variants associated with ever-smoking lung cancer. Results: Five novel independent loci, GABRA4 , intergenic region 12q24.33 , LRRC4C , LINC01088, and LCNL1 were identified with the association at two or three populations ( P −8 ). Further functional analysis provided multiple lines of evidence suggesting the variants affect lung cancer risk through excessive DNA damage ( GABRA4 ) or cis -regulation of gene expression ( LCNL1 ). The risk of variants from 12 independent regions, including the well-known CHRNA5 , associated with ever-smoking lung cancer was evaluated for never-smokers, light-smokers (packyear ≤ 20), and moderate-to-heavy-smokers (packyear > 20). Different risk patterns were observed for the variants among the different groups by smoking behavior. Conclusions: We identified novel variants associated with lung cancer in only ever- or never-smoking groups that were missed by prior main-effect association studies. Impact: Our study highlights the genetic heterogeneity between ever- and never-smoking lung cancer and provides etiologic insights into the complicated genetic architecture of this deadly cancer.
Year:
2024
Collaborators (31)
Rayjean Hung
University of Toronto
Susan M. Rosenberg
Ben F Love Chair in Cancer Research and professor
Baylor College of Medicine
Jun Xia
assistant professor
Texas A&M University
Yanhong Liu
Associate Professor
Baylor College of Medicine
Yun-Chul Hong
Seoul National University College of Medicine
Sanjay Shete
The University of Texas MD Anderson Cancer Center
David Christiani
Harvard University
Adonina Tardon
Coordinating Professor of the Doctoral Program in Medicine and Epidemiology
Universidad Antonio de Nebrija
Christopher I. Amos
Associate Director for Population and Data Science
Baylor College of Medicine
Melinda Aldrich
Vanderbilt University Medical Center
Susan Pinney
University of Cincinnati
Stig E. Bojesen
Copenhagen University Hospital
Chao Cheng
Associate Professor
Baylor College of Medicine
Ann G. Schwartz
Wayne State University School of Medicine
Kristen S. Purrington
Associate Professor
Wayne State University School of Medicine
John Field
Professor
University of Liverpool
Yohan Bossé
Laval University
Ryan Sun
Assistant Professor
The University of Texas MD Anderson Cancer Center
Joan Bailey-Wilson
Co-Branch Chief
National Human Genome Research Institute
Philip Lazarus
Professor
University at Buffalo
Matthew Schabath
Program Leader and Senior Member
H Lee Moffitt Cancer Center and Research Institute
Loic Le Marchand
Professor
University of Hawaii
Mikael Johansson
Ass professor
Umea University
Michael Peter Alan Davies
Roy Castle Lung Cancer Foundation Senior Research Fellow
University of Liverpool
Jian-Rong Li
Assistant Professor
Chang Gung University
Jinyoung Byun
Associate Professor
University of New Mexico
Mattias Johansson
Scientist
International Agency for Research on Cancer
Susanne Arnold
University of Kentucky
Geoffrey Liu
The M. Qasim Choksi Chair in Lung Cancer Translational Research
University of Toronto
Ping Yang
Professor
Mayo Clinic Arizona
Chu Chen
Full Member
Fred Hutchinson Cancer Research Center
Make your next move.
Prepare your application
Review drafts before you send them.